Serveur d'exploration sur la maladie de Parkinson

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease

Identifieur interne : 001846 ( Main/Exploration ); précédent : 001845; suivant : 001847

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease

Auteurs : Fabrizio Stocchi ; Stefano Ruggieri ; Laura Vacca ; C. Warren Olanow [États-Unis]

Source :

RBID : ISTEX:BDFF0EC7C209CC7C3F856B7BC5EF6B216243E7F7

English descriptors

Abstract

Motor complications are a major source of disability for patients with advanced Parkinson’s disease. Surgical therapies provide benefit to some, but these treatments are expensive and associated with adverse effects. Current research indicates that motor complications are associated with abnormal, intermittent, pulsatile stimulation of denervated dopamine receptors using short acting dopaminergic agents such as levodopa. Retrospective studies suggest that the use of longer‐acting more continuous dopaminergic therapies can improve both motor fluctuations and dyskinesia. We performed a prospective, long‐term (4‐year) trial comparing patients randomized to receive subcutaneous infusion of the dopamine agonist lisuride versus conventional therapy with oral levodopa and dopamine agonists. We demonstrate that patients receiving lisuride infusions experienced a significant reduction in both motor fluctuations and dyskinesia compared with patients receiving standard dopaminergic therapies. Benefits persisted for the 4‐year duration of the study. Mean Unified Parkinson’s Disease Rating Scale scores in ‘ON’ and ‘OFF’ states did not significantly change between baseline and 4 years for patients in the lisuride group, but deteriorated in patients in the levodopa group. This study indicates that continuous lisuride infusion can be beneficial for patients with advanced Parkinson’s disease and reverse established motor fluctuations and dyskinesia.

Url:
DOI: 10.1093/brain/awf214


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease</title>
<author>
<name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
</author>
<author>
<name sortKey="Ruggieri, Stefano" sort="Ruggieri, Stefano" uniqKey="Ruggieri S" first="Stefano" last="Ruggieri">Stefano Ruggieri</name>
</author>
<author>
<name sortKey="Vacca, Laura" sort="Vacca, Laura" uniqKey="Vacca L" first="Laura" last="Vacca">Laura Vacca</name>
</author>
<author>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BDFF0EC7C209CC7C3F856B7BC5EF6B216243E7F7</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1093/brain/awf214</idno>
<idno type="url">https://api.istex.fr/document/BDFF0EC7C209CC7C3F856B7BC5EF6B216243E7F7/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">001328</idno>
<idno type="wicri:Area/Main/Curation">001120</idno>
<idno type="wicri:Area/Main/Exploration">001846</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease</title>
<author>
<name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation>
<wicri:noCountry code="subField"></wicri:noCountry>
</affiliation>
<affiliation>
<wicri:noCountry code="subField"></wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Ruggieri, Stefano" sort="Ruggieri, Stefano" uniqKey="Ruggieri S" first="Stefano" last="Ruggieri">Stefano Ruggieri</name>
<affiliation>
<wicri:noCountry code="subField"></wicri:noCountry>
</affiliation>
<affiliation>
<wicri:noCountry code="subField"></wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Vacca, Laura" sort="Vacca, Laura" uniqKey="Vacca L" first="Laura" last="Vacca">Laura Vacca</name>
<affiliation>
<wicri:noCountry code="subField"></wicri:noCountry>
</affiliation>
<affiliation>
<wicri:noCountry code="subField"></wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
<affiliation>
<wicri:noCountry code="subField"></wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Brain</title>
<title level="j" type="abbrev">Brain</title>
<idno type="ISSN">0006-8950</idno>
<idno type="eISSN">1460-2156</idno>
<imprint>
<publisher>Oxford University Press</publisher>
<date type="published" when="2002-09">2002-09</date>
<biblScope unit="volume">125</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="2058">2058</biblScope>
<biblScope unit="page" to="2066">2066</biblScope>
</imprint>
<idno type="ISSN">0006-8950</idno>
</series>
<idno type="istex">BDFF0EC7C209CC7C3F856B7BC5EF6B216243E7F7</idno>
<idno type="DOI">10.1093/brain/awf214</idno>
<idno type="local">awf214</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0006-8950</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Abbreviations: AIMS = Abnormal Involuntary Movements Scale; MPTP = 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine; UPDRS = Unified Parkinson’s Disease Rating Scale</term>
<term>Keywords: lisuride; Parkinson’s disease; randomized trial; prospective trial; dyskinesia</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Motor complications are a major source of disability for patients with advanced Parkinson’s disease. Surgical therapies provide benefit to some, but these treatments are expensive and associated with adverse effects. Current research indicates that motor complications are associated with abnormal, intermittent, pulsatile stimulation of denervated dopamine receptors using short acting dopaminergic agents such as levodopa. Retrospective studies suggest that the use of longer‐acting more continuous dopaminergic therapies can improve both motor fluctuations and dyskinesia. We performed a prospective, long‐term (4‐year) trial comparing patients randomized to receive subcutaneous infusion of the dopamine agonist lisuride versus conventional therapy with oral levodopa and dopamine agonists. We demonstrate that patients receiving lisuride infusions experienced a significant reduction in both motor fluctuations and dyskinesia compared with patients receiving standard dopaminergic therapies. Benefits persisted for the 4‐year duration of the study. Mean Unified Parkinson’s Disease Rating Scale scores in ‘ON’ and ‘OFF’ states did not significantly change between baseline and 4 years for patients in the lisuride group, but deteriorated in patients in the levodopa group. This study indicates that continuous lisuride infusion can be beneficial for patients with advanced Parkinson’s disease and reverse established motor fluctuations and dyskinesia.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>État de New York</li>
</region>
</list>
<tree>
<noCountry>
<name sortKey="Ruggieri, Stefano" sort="Ruggieri, Stefano" uniqKey="Ruggieri S" first="Stefano" last="Ruggieri">Stefano Ruggieri</name>
<name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<name sortKey="Vacca, Laura" sort="Vacca, Laura" uniqKey="Vacca L" first="Laura" last="Vacca">Laura Vacca</name>
</noCountry>
<country name="États-Unis">
<region name="État de New York">
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001846 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001846 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:BDFF0EC7C209CC7C3F856B7BC5EF6B216243E7F7
   |texte=   Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024